FISHAWACK-GROUP
The Fishawack Group of Companies , one of the world’s largest independent medical communications organisations, has acquired Healthcircle Advertising Limited , a strategic brand communications agency with offices in London and Portugal.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180709005905/en/
“This acquisition is a major step in Fishawack’s plan to build a global strategic creative agency that can work alongside our medical communications business, ” explained Oliver Dennis , Chief Executive Officer of the Fishawack Group. “We also acquired US-based Carling Communications in July last year. Carling needed critical mass in Europe and Healthcircle needed a US partner. This is a great match and positions us to deliver integrated creative and medcomms solutions for clients on a truly global scale.”
Mike Taylor , Managing Director of Healthcircle added, “We’ve been on the lookout for a partner to support our growth in the US whilst also providing us access to scientific and strategic talent. Healthcircle and Fishawack have already collaborated extensively and we’ve known and worked with many of the Carling team over our years in the business.”
Gail Flockhart , Group Managing Director at Fishawack said, “All agencies are collections of people with different talents. What makes us different is the investment we make in establishing real chemistry between teams so that collaboration is fun and triggers new ideas. We’re still at a size where we can make this meaningful.”
About the Fishawack Group
The Fishawack Group of Companies is one of the largest independent medical communications specialists, with offices in the UK (Knutsford, Oxford, and Brighton), the USA (Philadelphia, PA, and San Diego, CA), Switzerland (Basel), and India (Hyderabad).
For over 17 years, Fishawack has been partnering with global and regional pharmaceutical, biotechnology, and medical device clients to develop and deliver services in the fields of medical communications, scientific engagement, market access, strategic consultancy, and thought leader consultancy. For more detailed information about our services, please see the Fishawack Group website at www.fishawack.com .
We have built our reputation on excellence, creativity, and transparency.
About Healthcircle
Healthcircle is a full-service strategic brand communications agency. With extensive experience in direct-to-patient communications, creative digital solutions and creative medcomms, Healthcircle has consistently won awards for its surprising and innovative creative work. Healthcircle is headquartered in London, UK, with an office in Cascais, Portugal.
Healthcircle strongly believes that connecting strategy and creative is the key to brand success and has demonstrated the success of this approach on some of the largest brands in the global pharmaceutical marketplace during the last 10 years. More information is available at www.healthcircle-uk.com
Fishawack Group of Companies
www.fishawack.com
Twitter:
@Fishawack
LinkedIn:
Fishawack Group of Companies
Headquarters:
100–102 King Street, Knutsford, Cheshire, WA16 6HQ, UK
Tel: +44
1565 756600
View source version on businesswire.com: https://www.businesswire.com/news/home/20180709005905/en/
Contact:
The Fishawack Group
Gail Flockhart
Group
Managing Director
gail.flockhart@fishawack.com
or
Healthcircle
Advertising Ltd
Mike Taylor
Managing Director
Mike.taylor@Healthcircle-uk.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 22:30:00 CEST | Press release
Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other investigational inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to exi
IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 22:05:00 CEST | Press release
IonQ and Einride will collaborate to develop quantum solutions for fleet routing, logistics optimization, and supply chain solutionsIonQ’s investment will grow its European presence and reinforce commitment to building a quantum economy in Sweden and the European market IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global frei
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 21:26:00 CEST | Press release
Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current s
NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 21:24:00 CEST | Press release
NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates
Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 21:08:00 CEST | Press release
As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom